AI Article Synopsis
- Laser-assisted drug delivery (LADD) is being explored as a method to effectively deliver tranexamic acid (TXA) for treating melasma, with a focus on its effectiveness and safety.
- A literature review identified five randomized controlled trials (RCTs) comparing LADD with laser or topical TXA alone, utilizing MASI/mMASI scores for clinical outcomes.
- The results demonstrated significant improvement with LADD, showing decreased MASI/mMASI scores and minimal adverse effects, suggesting that this method is a promising treatment option for melasma.
Article Abstract
Laser-assisted drug delivery (LADD) is a new treatment for delivering drugs within the skin. This meta-analysis investigates the effectiveness and safety of the laser-assisted delivery of tranexamic acid (TXA) to treat melasma. A literature review was conducted by searching publication platforms to search for randomized controlled trials (RCTs) that compared laser-assisted delivery of TXA with laser-alone or topical TXA-alone treatment. The Embase, Web of Science, PubMed, Google Scholar, and Cochrane Library databases were searched, and Melasma Area Severity Index (MASI)/modified MASI (mMASI) scores used as the clinical improvement outcomes. All statistical analyses were performed using the RevMan software (Review Manager, V.5.3). The standardized mean differences and 95% confidence intervals were used to assess the results. Five RCTs were included in this meta-analysis. These studies used ablative fractional photothermolysis and nonablative dermal remodeling laser modalities. The results showed that both laser modalities combined with TXA significantly decreased the MASI/mMASI scores (P = .0003). Furthermore, no serious adverse events were observed, except mild erythema and burning pain. The meta-analysis found that the laser-assisted delivery of TXA is a new effective and safe treatment option for melasma treatment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14764172.2022.2148186 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nanoparticle-Mediated Explosive Anti-PD-L1 Factory Built in Tumor for Advanced Immunotherapy.
Adv Mater
January 2025
Department of Chemistry, POSTECH-CATHOLIC Biomedical Engineering Institute, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea.
Immunotherapy, particularly immune checkpoint blockade (ICB) therapies, has revolutionized oncology. However, it encounters challenges such as inadequate drug accumulation and limited efficacy against "cold" tumors characterized by lack of T cell infiltration and immunosuppressive microenvironments. Here, a controlled antibody production and releasing nanoparticle (CAPRN) is introduced, designed to augment ICB efficacy by facilitating tumor-targeted antibody production and inducing photodynamic cell death.
View Article and Find Full Text PDFA review of chitosan role in milk bioactive-based drug delivery, smart packaging and biosensors: Recent advances and developments.
Int J Biol Macromol
December 2024
Nanotechnology Department, School of Advanced Technologies, Iran University of Science and Technology (IUST), Tehran, Iran. Electronic address:
Chitosan, a versatile biopolymer derived from chitin, is increasingly recognized in the milk industry for its multifunctional applications in drug delivery, smart packaging, and biosensor development. This review provides a comprehensive analysis of recent advances in chitosan production techniques. These include chemical, biological, and novel methods such as deep eutectic solvents (DES), microwave-assisted approaches, and laser-assisted processes.
View Article and Find Full Text PDFFractional erbium-doped yttrium aluminum garnet laser-assisted drug delivery: impact of triamcinolone acetonide formulation on drug permeation.
Drug Deliv Transl Res
December 2024
Department of Dermatology, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.
Ablative fractional laser-assisted drug delivery has gained attention as a promising method for enhancing dermal drug absorption and improving therapeutic outcomes in dermatological conditions, particularly for hypertrophic and keloid scars. However, despite the growing number of clinical trials and case reports supporting its efficacy, there remains a scarcity of robust evidence on the topical bioavailability and dermato-pharmacokinetics of drugs in human subjects. This study aimed to examine the enhancement of triamcinolone acetonide (TAC) bioavailability following treatment with a fractional Erbium-Doped Yttrium Aluminum Garnet (Er: YAG) laser.
View Article and Find Full Text PDFCombined fractional CO2 laser 10,600 nm with methotrexate 1% gel versus methotrexate 1% gel alone in the treatment of nail psoriasis: a randomized comparative study.
Arch Dermatol Res
December 2024
Department of Dermatology and Venereology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt.
Methotrexate injections intralesionally as a treatment for psoriatic nails proved to be effective in large-scale studies as well as individual case reports, but the process is painful and time-consuming. The objective of this study was to compare the efficacy and safety of combined fractional CO2 laser (Fr. CO2) 10,600 nm and methotrexate gel versus methotrexate 1% gel alone in treatment of nail psoriasis.
View Article and Find Full Text PDFManagement of Keloids and Hypertrophic Scars.
Am Fam Physician
December 2024
Full Circle Health, Boise, Idaho.
Keloid and hypertrophic scars are a result of aberrant wound healing responses within the reticular dermis. They are thought to be secondary to the formation of a disorganized extracellular matrix due to excessive fibroproliferative collagen response. Prevention of these scars focuses on avoiding elective or cosmetic procedures such as piercings in patients at high risk, reducing tension across the lesion, and decreasing the inflammatory response.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!